



**HAL**  
open science

# Dying-back of ascending noradrenergic projections in Parkinson's disease

Rick Helmich, Stéphane Lehéricy

► **To cite this version:**

Rick Helmich, Stéphane Lehéricy. Dying-back of ascending noradrenergic projections in Parkinson's disease. *Brain - A Journal of Neurology*, In press, 10.1093/brain/awab286 . hal-03346224

**HAL Id: hal-03346224**

<https://hal.sorbonne-universite.fr/hal-03346224v1>

Submitted on 16 Sep 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## SCIENTIFIC COMMENTARY

## **Dying-back of ascending noradrenergic projections in Parkinson's disease**

**This scientific commentary refers to ‘Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinson's disease’, by Doppler *et al.* (doi:10.1093/brain/awab236).**

Parkinson's disease is a neurodegenerative disorder characterized by progressive loss of nigro-striatal dopamine neurons. The cardinal motor signs of the disease, particularly bradykinesia and rigidity – and to a lesser extent tremor – have been linked to dopaminergic dysfunction of the basal ganglia. In addition, it has long been known that Parkinson's disease patients also have profound noradrenergic, cholinergic and serotonergic cell loss. Clinically, noradrenergic deficits have been linked to cognitive dysfunction, to specific non-motor symptoms such as REM-sleep behavioural disorder (RBD), and to axial symptoms such as freezing of gait.<sup>1,2</sup>

A key outstanding question is how Parkinson's disease propagates through the brain, and what this pattern tells us about the underlying mechanisms of progressive cell death. The classical post-mortem studies by Braak and colleagues have suggested that there is a bottom-up progression of disease, which may initially start in the gut, before progressing towards caudal and later more rostral parts of the brainstem, and ultimately reaching the cortex.

Other studies point to the role of top-down pathophysiological mechanisms, where increased cortical demands may lead to energetic failure in the highly branched dopaminergic and noradrenergic neurons, causing them to dysfunction and ultimately perish.<sup>3</sup> The clinical

© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com)

observation that motor symptoms in Parkinson's disease can start out very localized (e.g. resting tremor of one hand, or bradykinesia of one foot) supports this idea, since this detailed level of somatotopy is observed much more clearly at cortico-striatal than at nigro-striatal projections.<sup>3</sup>

In addition, several recent studies have shown important inter-individual differences in disease propagation patterns, which are linked to the expression of clinical symptoms such as the presence or absence of RBD.<sup>4,5</sup> In this issue of *Brain*, Doppler and colleagues address some of these issues, by using neuroimaging techniques to decipher the anatomical pattern of noradrenergic dysfunction in Parkinson's disease.<sup>6</sup>

In a comprehensive study, Doppler *et al.* used a combination of two imaging techniques to measure different compartments of the noradrenergic system: PET with <sup>11</sup>C-MeNER (Figure 1B), a reboxetine analogue that binds specifically to noradrenaline transporters located at the terminal sites of noradrenergic cells, and neuromelanin-sensitive MRI (Figure 1C), which is a turbo spin-echo (TSE) T1-weighted sequence that is sensitive to the loss of pigmented neurons in the locus coeruleus (LC).

The LC is a small nucleus in the dorsal pons that is the primary source of noradrenergic projections in the brain (Figure 1A). In 47 patients with Parkinson's disease and 26 healthy controls, Doppler *et al.* applied both techniques within a timespan of a few weeks. The authors hypothesized that more severe deficits would be seen at the level of the noradrenergic terminals (PET) than the cell bodies (MRI), in line with findings in the dopaminergic system, where a 'dying-back' mechanism of neurodegeneration has been found in Parkinson's disease. They also tested for regional differences in neurodegeneration within the LC, by comparing rostral, intermediate, and caudal portions of the LC.

There are three main findings. First, and most importantly, the authors found that pronounced axonal damage *exceeded* somatic damage of the noradrenergic system in patients, as has been

found also for the dopaminergic system. This effect was quantified as a smaller ratio of  $^{11}\text{C}$ -MeNER PET to neuromelanin-MRI contrast in Parkinson's disease patients, compared to healthy controls (Figure 1D). The authors refer to this effect as 'uncoupling', which should be understood as disproportionately large noradrenergic deficits at the distal ends of the axonal tree. This effect may be related to the extremely large arborization of both dopaminergic and noradrenergic neurons.<sup>3</sup> This anatomical configuration makes these ascending neurotransmitter systems particularly vulnerable to insults.

The findings do not immediately demonstrate where such insults could come from: the 'dying-back' of noradrenergic cells may be the outcome of different pathophysiological processes that can be either bottom-up (e.g. alpha synuclein affecting the cell bodies in the LC), top-down (e.g. altered synaptic demands at projection sites, or cortico-fugal projections to the LC), or a combination of both. Cellular mechanisms such as impaired protein clearance, altered mitochondrial function, inflammation, and management of reactive oxygen species have all been proposed to play a role in cell death in Parkinson's disease.<sup>7</sup> Furthermore, recent development of a rodent model exhibiting an age-dependent production of human-like neuromelanin in the substantia nigra has led to the hypothesis that too much intracellular neuromelanin accumulation may compromise neuronal function and trigger a Parkinson's disease-like pathology.<sup>8</sup>

A second finding by Doppler and colleagues is that there was no correlation between MRI and PET findings, either in healthy controls or in patients with Parkinson's disease. This could be another instance of the 'uncoupling' between noradrenergic terminals and cell bodies. The fact that there was no correlation in control subjects may suggest that the two compartments of the noradrenergic system are independent of each other in the physiological situation. This would be surprising, since the noradrenergic terminals are ultimately connected to the cell bodies in the LC. Alternatively, the lack of correlation could be driven by methodological factors, such

as different sensitivity of PET and MRI to the underlying biology, large variability of signal and volume measurements in the LC using MRI, and lack of statistical power owing to a moderate number of patients. In addition, the subjects' RBD status, which was not considered, may also contribute: disease propagation patterns have been found to differ between Parkinsonian patients with and without RBD.<sup>5</sup>

A third novel finding reported by Doppler and colleagues is that there were regional differences in the spatial pattern of LC damage in Parkinson's disease, such that the middle and caudal portions of the LC were more affected than the rostral portion of the LC. These data are roughly in line with recent post-mortem investigations in Parkinson's disease, although the differences between LC subregions are relatively small. It would be interesting to study this pattern in relation to the presence of RBD, which is probably linked to the involvement of the locus subcoeruleus located in the caudal part of the LC.<sup>2</sup> Interestingly, these effects were asymmetric in nature, being more pronounced in the hemisphere contralateral to the clinically most-affected side.

The authors did not report correlations between noradrenergic deficits and clinical symptoms. This is partly due to the fact that different cohorts were combined, and unfortunately there was no homogeneous evaluation of non-motor symptoms across all individuals. Surprisingly, there was no correlation between noradrenergic dysfunction and progression markers of Parkinson's disease, such as disease duration, Hoehn & Yahr stage, and total Unified Parkinson's Disease Rating Scale (UPDRS) score. On the other hand, these findings are in line with another recent neuromelanin-sensitive MRI study in Parkinson's disease, which showed that motor severity correlated only with neuromelanin in the substantia nigra, while cognitive measures only correlated with neuromelanin signal in the LC.<sup>1</sup>

Doppler and colleagues measured performance on the Montreal Cognitive Assessment (MoCA), which was included as a covariate of no interest in the analyses. While the MoCA is a useful screening tool, it is not sensitive enough to detect subtle cognitive deficits in Parkinson's disease, and it is not specific enough to localize these deficits to anatomical circuits.<sup>1</sup> It would be interesting to test if the dying-back of the noradrenergic system is associated with specific patterns of cognitive deficits in Parkinson's disease. Within the motor domain, there may be a relationship between noradrenergic deficits and tremor severity. <sup>11</sup>C-MeNER PET studies have shown that the noradrenergic system is relatively spared in tremor-dominant Parkinson's disease patients, who also have relatively spared cognitive function. Furthermore, noradrenergic excitation of the thalamus has recently been linked to the increase of Parkinson's tremor during cognitive stress, which is a well-known clinical observation.<sup>9</sup> More specifically, while tremor is likely generated by dopamine-dependent changes in the basal ganglia and the cerebello-thalamo-cortical loop, relatively preserved noradrenergic projections to the thalamus modulate tremor amplitude during arousal.<sup>9</sup> Hence, both a spared and a degenerated noradrenergic system may contribute to clinical symptoms in Parkinson's disease. This shows that the pathophysiology of Parkinson's disease involves a complex cocktail of neurotransmitter changes, where the whole is greater than the sum of the parts. The absence of correlations between clinical measures of Parkinson's disease duration and the effects reported here is perhaps not so surprising, given emerging evidence that different subgroups of patients have different disease propagation routes. The question of how Parkinson's disease travels through the brain can then only be answered in large datasets, where detailed clinical and cognitive phenotyping along multiple axes is available. The current study provides an excellent point of departure to start unravelling these issues.

*Rick C. Helmich<sup>1</sup> and Stéphane Lehéricy<sup>2</sup>*

*1 Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Centre for Cognitive Neuroimaging and Centre of Expertise for Parkinson & Movement Disorders, Nijmegen, The Netherlands*

*2 Institut du Cerveau – Paris Brain Institute (ICM), Centre de NeuroImagerie de Recherche (CENIR), Team “Movement Investigations and Therapeutics” (MOV’IT), Sorbonne Université, INSERM U1127, CNRS 7225, Paris, France*

Correspondence to: Rick Helmich

E-mail: rick.helmich@radboudumc.nl

## **Funding**

R.C.H. is supported by the Netherlands Organization for Scientific Research and the Michael J. Fox Foundation. S.L. received grants from 'Investissements d’avenir' [grant number ANR-10-IAIHU-06 and ANR-11-INBS-0006] and research grant from BIOGEN Inc.

## **Competing interests**

The authors report no competing interests.

## **Figure legend**

**Figure 1 ‘Dying-back’ of noradrenergic projections in Parkinson’s disease. (A)** Noradrenergic neurons in the LC project to cortical and subcortical brain regions (modified


from <sup>10</sup>). (B) The density of noradrenergic terminals, shown with <sup>11</sup>C-MeNER PET (taken from Suppl. Fig 1 and Fig 5).<sup>6</sup> (C) The structural integrity of the LC (indicated in red), as compared to a control region (pons), using neuromelanin-sensitive MRI (taken from Fig 1).<sup>6</sup> (D) The ratio between PET and MRI signal shown for the hypothalamus (taken from Fig 7).<sup>6</sup> Data were normalized to the average in healthy controls. In patients, the significantly lower ratio means that noradrenergic dysfunction of the terminals (PET) exceeded that of the cell bodies (MRI). DVR, distribution volume ratio; LC, locus coeruleus.

## References

1. Prasuhn J, Prasuhn M, Fellbrich A, et al. Association of locus coeruleus and substantia nigra pathology with cognitive and motor functions in patients with Parkinson disease. *Neurology*. Published online 29 June 2021. doi:10.1212/WNL.00000000000012444
2. Garcia-Lorenzo D, Longo-Dos Santos C, Ewencyk C, et al. The coeruleus/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson's disease. *Brain*. 2013;136(7):2120–2129.
3. Foffani G, Obeso JA. A Cortical Pathogenic Theory of Parkinson's Disease. *Neuron*. 2018;99(6):1116–1128.
4. Horsager J, Andersen KB, Knudsen K, et al. Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study. *Brain* 2020;31:1114–12.
5. Pyatigorskaya N, Yahia-Cherif L, Valabrègue R, et al. Parkinson Disease Propagation Using MRI Biomarkers and Partial Least Squares Path Modeling. *Neurology* 2021;96(3):e460–e471.



6. Doppler CEJ, Kinnerup MB, Brune C, et al. Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinson's disease. *Brain*. 2021;awab236. doi:10.1093/brain/awab236
7. Giguère N, Burke Nanni S, Trudeau L-E. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease. *Front Neur*. 2018;9:455.
8. Carballo-Carbajal I, Laguna A, Romero-Giménez J, et al. Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson's disease pathogenesis. *Nat Commun*. 2019;10(1):973–19.
9. Dirx MF, Zach H, van Nuland AJ, et al. Cognitive load amplifies Parkinson's tremor through excitatory network influences onto the thalamus. *Brain*. 2020;143(5):1498–1511.
10. Augusto E, Gambino F. Can NMDA Spikes Dictate Computations of Local Networks and Behavior? *Front Mol Neurosci*. 2019;12:238.



336x153mm (300 x 300 DPI)